Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this podcast, Spencer H. Durham, PharmD, BCPS, BCIDP; Stefan Gravenstein, MD, MPH; and Barbara Resnick, PhD, CRNP, discuss risk factors for respiratory syncytial virus among adults, the need for a vaccination strategy in this population, and the evolving clinical studies on vaccines for older adults. Following their dialogue, the faculty field questions from healthcare professionals.
Spencer H. Durham, PharmD, BCPS, BCIDP
Associate Clinical Professor of Pharmacy Practice
Director, Alumni & Professional Affairs Clinical Affairs & Outreach
Auburn University Harrison School of Pharmacy
Stefan Gravenstein, MD, MPH
Division of Geriatrics and Palliative Medicine
The Warren Alpert Medical School of Brown University
Providence, Rhode Island
Barbara Resnick, PhD, CRNP
School of Nursing
University of Maryland
Roland Park Place
Expert commentary on current vaccine candidates for RSV, from Dr. Spencer H. Durham and Clinical Care Options (CCO)
From Elliott Bosco, PharmD, and Clinical Care Options (CCO), expert commentary on the risks and costs of RSV to older adults in the United States
Video from CCO: overview of respiratory syncytial virus illness and vaccine development in older adults from Drs. Spencer Durham, Stefan Gravenstein, and Barbara Resnick.
CCO slides: overview of RSV illness and vaccine development in older adults.